DGFT Minutes

Government of India/ भारत सरकार

Ministry of Commerce and Industry/ वाि णज्य और उद्योगमंत्रालय Department of Commerce/ वाि णज्यज्यवभाग

Directorate General of ForeignTrade,Delhi/ ि वदेश व्यापार महाि नदेशालय , ि दल्ली

VANIJYABHAWAN,AKBARROAD,CENTRALDELHI,DELHI,110011/ वाि णज्यभवन , अकबररोड , नििदल्ली Email Office : dgft@nic.in, Phone Office :011-23062777

MINUTES OF MEETING

Meeting No - NC/3/MEET/May/202425/4 Meeting Date - 06/06/2024

Minutes of the Norms Committee–3 Meeting No.NC/3/MEET/May/202425/4 dated 06/06/2024 (Manual Case) under the Chairmanship of Shri Rakesh Kumar, Addl. DGFT for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2023 pertaining to Chemical and Allied products falling under Chapter 29 and 30.

2. The following members were present in the Meeting:-

3. The Norms Committee has taken decision only with respect to technical aspect/ wastage norms. While redeeming the application, RAs should check that the applicant has fulfilled all requirements as prescribed in policy/procedure including those in notifications, public notices and policy circulars issued from time to time or any other provisions under FTP/HBP for issuance of Advance Authorization and regularization of the case.

4. RAs shall also ensure compliance of SION, General Notes and Chapter Notes wherever applicable.

er provisions under FTP/HBP for issuance of Advance Authorization and regularization of the case.

4. RAs shall also ensure compliance of SION, General Notes and Chapter Notes wherever applicable.

5. RAs shall ensure that authorization is issued or redeemed based on the wastages/consumption as ratified by the Committee or as per wastages claimed in the application, whichever is less. In this regard full compliance of the provisions of Para 4.12 of FTP, Para 4.16; Para 4.21; and Para 4.51 of HBP shall be made.

Manual Application for Personal Hearing Held on 06/06/2024.

to the firm.||||||||-| |||Decision:Shri Deepak Maduskar, Vice President (Supply Chain) and Dr. Shireesh Ambhaik<br>Technical Lead of the firm attended the Personal Hearing and explained the case. The fi<br>explained that they are importing raw material (i) Riboflavin (Vitamin B2) from DSM Nutritio|||||||||||| ||||||||||||||| |||<br>the committee ha||p p<br>decided torevise ad-hoc norms on the basis of information rovided b the fi|||||||||| |||<br>d||<br>lid hih i l||||||p y|||| |||as uner, or as ap||e wcever s ess: -|||||||||| ||||||||||||||| |||Export Product||||||Qty.|Sl.<br>N|Import Item||Qty.<br>lld|| ||||||||||o.|||aowe.|| |||Riboflavin Sodiu||Phoshate Hdrate||||1 k|1|Riboflavin (Vitamine B2)||130 k|| |||<br>EP 11.2||p y||||g.||||. g.|| ||||||||||2|Pyridine||2.00 kg.|| ||||||||||3|<br>Acetonitrile||<br>1.73 kg.|| |4<br>Phosphorus Oxychloride<br>2.00 kg.<br>Note: (i) Above ad-hoc norms are valid only for export to DSM Nutritional Product AG<br>Switzerland<br>under<br>Contract<br>Manufacturing<br>Agreement<br>between<br>DSM<br>Switzerland and M/s Supriya Lifescience Limited.<br>(ii) No further Advance Authorisation on the above norms will be considered an<br>further Advance Authorisation to be considered based on revised yields an<br>consumption data.<br>(iii) Above norms are for EP 11.2 only and not for any other Pharmaceutica<br>specification like EP/BP/USP etc.<br>RA concerned may take further necessary action as per the above decision of Nor<br>**Committee and the co

1.2 only and not for any other Pharmaceutica**<br>specification like EP/BP/USP etc.<br>RA concerned may take further necessary action as per the above decision of Nor<br>Committee and the conditions attached with the Norms.|||||||||4|Phosphorus Oxychloride||2.00 kg.|| |||Note: (i) Above ad-hoc norms are valid only for export to DSM Nutritional Product AG<br>Switzerland<br>under<br>Contract<br>Manufacturing<br>Agreement<br>between<br>DSM<br>Switzerland and M/s Supriya Lifescience Limited.<br>(ii) No further Advance Authorisation on the above norms will be considered an<br>further Advance Authorisation to be considered based on revised yields an|||||||||||| |||consum<br>(iii) Above||ption dat<br>norms||a.<br>re for|EP 112 onl and not for an other Ph||||armaceutic||| |||<br>specifi||<br>cation lik||<br>e EP/BP|. y y<br>/USP etc.||||||| |||RA concerned<br>Committee and t||may take<br>he conditi||furthe<br>ons atta|r necessary action as per the above decis<br>ched with the Norms.||||ion of Nor||ms| |||||||||||||||